According to CNS Response, the new patent presents novel use of the company’s protected methodology for development of new indications of FDA approved pharmaceuticals when using an EEG computer analysis.
Len Brandt, CEO of CNS Response, said: “One of the most compelling opportunities in pharmaceutical marketing is the ability to expand new indications for already approved medications.
“With the successful completion of our multisite study for the treatment of resistant depression, I believe we will have demonstrated the utility of the rEEG technology not only to physicians treating behavioral illness, but also to the pharmaceutical industry including ways described in this patent.”